Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499967 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 202
- Enrollment target
NCT00499967 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 202 participants.
The verdict
NCT00499967, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
Interventions
- DRUG Placebo
- DRUG GS-9191 ointment
- DRUG GS-9191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499967
The ClinicalTrials.gov registry entry for NCT00499967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00499967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499967 about?
NCT00499967 is a clinical study titled "Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts". The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
What is the current status of trial NCT00499967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 202 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00499967?
The interventions under investigation include: Placebo (DRUG), GS-9191 ointment (DRUG), GS-9191 (DRUG).
Who is sponsoring clinical trial NCT00499967?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.